ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

HHS Orders Gallo Forum Canceled; Meeting May Be Held After OSI report final – Calabresi

July 3, 1992

Letter To The Editor: Prevention Research Requires Rigor And Collaboration.

June 20, 2003

Bonadonna, Fisher Share %50,000 Bristol-Myers Award

April 23, 1993

Modeling Will Be Used For Other Populations

November 26, 2010

Obesity, Faster Weight Gain, Linked To Poor Prognosis

October 28, 2005

NCI’s SBIR Awards Move Up In Quality; Congress considers Making It Permanent; FASEB Object

September 19, 1986